Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 11/20 | 0.45 |
| ▸ | NR1I2 | O75469 | 5/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | ERN1 | O75460 | 1/20 | 0.37 |
| ▸ | PIK3CA | P42336 | 6/20 | 0.37 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.37 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.37 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.37 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.37 |
| ▸ | MTOR | P42345 | 4/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL574872 | 0.89 | BRAF (0.47) | BRAFNR1I2ERN1PIK3CAPIK3CD | |
| SCHEMBL574488 | 0.88 | BRAF (0.48) | BRAFNR1I2ERN1PIK3CAPIK3CD | |
| SCHEMBL15191850 | 0.88 | BRAF (0.46) | BRAFNR1I2ERN1PIK3CAPIK3CD | |
| SCHEMBL15191977 | 0.85 | BRAF (0.47) | BRAFNR1I2CYP3A4ERN1PIK3CA | |
| SCHEMBL574829 | 0.85 | BRAF (0.44) | BRAFNR1I2ERN1PIK3CAMTOR | |
| SCHEMBL574918 | 0.84 | BRAF (0.46) | BRAFNR1I2CYP3A4ERN1PIK3CA | |
| SCHEMBL15191889 | 0.83 | BRAF (0.45) | BRAFNR1I2CYP3A4ERN1PIK3CA | |
| SCHEMBL15192467 | 0.83 | BRAF (0.45) | BRAFNR1I2PIK3CA | |
| SCHEMBL15191845 | 0.83 | BRAF (0.43) | BRAFNR1I2ERN1PIK3CAMTOR | |
| SCHEMBL574939 | 0.83 | BRAF (0.43) | BRAFNR1I2ERN1PIK3CA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9114137-B2 | Derivatives of pyrazolophenyl-benzenesulfonamide compounds and use thereof as antitumor agents | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2015-08-25 | — | — | US | claimed |
| CN-103153980-B | Derivatives of pyrazolophenylbenzenesulfonamide compounds and their use as antitumor agents | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2015-12-16 | — | — | CN | disclosed |
| EP-2601185-B1 | DERIVATIVES OF PYRAZOLOPHENYL-BENZENESULFONAMIDE COMPOUNDS AND USE THEREOF AS ANTITUMOR AGENTS | NERVIANO MEDICAL SCIENCES SRL (IT) | 2015-10-07 | — | — | EP | disclosed |
| EP-2601185-B1 | DERIVATIVES OF PYRAZOLOPHENYL-BENZENESULFONAMIDE COMPOUNDS AND USE THEREOF AS ANTITUMOR AGENTS | NERVIANO MEDICAL SCIENCES SRL (IT) | 2015-10-07 | — | — | EP | disclosed |
| US-9114137-B2 | Derivatives of pyrazolophenyl-benzenesulfonamide compounds and use thereof as antitumor agents | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2015-08-25 | — | — | US | disclosed |
| US-9114137-B2 | Derivatives of pyrazolophenyl-benzenesulfonamide compounds and use thereof as antitumor agents | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2015-08-25 | — | — | US | disclosed |
| US-9114137-B2 | Derivatives of pyrazolophenyl-benzenesulfonamide compounds and use thereof as antitumor agents | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2015-08-25 | — | — | US | disclosed |
| US-20130217715-A1 | DERIVATIVES OF PYRAZOLOPHENYL-BENZENESULFONAMIDE COMPOUNDS AND USE THEREOF AS ANTITUMOR AGENTS | LSI FINANCING 1 DESIGNATED ACTIVITY COMPANY (IE) | 2013-08-22 | — | — | US | disclosed |
| US-20130217715-A1 | DERIVATIVES OF PYRAZOLOPHENYL-BENZENESULFONAMIDE COMPOUNDS AND USE THEREOF AS ANTITUMOR AGENTS | LSI FINANCING 1 DESIGNATED ACTIVITY COMPANY (IE) | 2013-08-22 | — | — | US | disclosed |
| US-20130217715-A1 | DERIVATIVES OF PYRAZOLOPHENYL-BENZENESULFONAMIDE COMPOUNDS AND USE THEREOF AS ANTITUMOR AGENTS | LSI FINANCING 1 DESIGNATED ACTIVITY COMPANY (IE) | 2013-08-22 | — | — | US | disclosed |
| EP-2601185-A1 | DERIVATIVES OF PYRAZOLOPHENYL-BENZENESULFONAMIDE COMPOUNDS AND USE THEREOF AS ANTITUMOR AGENTS | Nerviano Medical Sciences S.r.l. (IT) | 2013-06-12 | — | — | EP | disclosed |
| CN-103153980-A | Derivatives of pyrazolophenylbenzenesulfonamide compounds and their use as antitumor agents | NERVIANO MEDICAL SCIENCES SRL | 2013-06-12 | — | — | CN | disclosed |
| WO-2012016993-A1 | DERIVATIVES OF PYRAZOLOPHENYL-BENZENESULFONAMIDE COMPOUNDS AND USE THEREOF AS ANTITUMOR AGENTS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2012-02-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130217715-A1 | DERIVATIVES OF PYRAZOLOPHENYL-BENZENESULFONAMIDE COMPOUNDS AND USE THEREOF AS ANTITUMOR AGENTS | CDK2, CDK1, CDK4 | BRAF 8/4885NR1I2 2530/4885CYP3A4 3639/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.